Janux Therapeutics Cash Flow Statement
NASDAQ: JANXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
18.39-0.11 (-0.59%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Janux Therapeutics free cash flow
In fiscal 2025, Janux Therapeutics generated -$82.2 million of operating cash flow and spent $1.0 million on capital expenditures. That left free cash flow of -$83.3 million, a free-cash-flow margin of -832.8% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Janux Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -113.63M | -68.99M | -58.29M | -63.06M | -32.67M | -6.78M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 2.03M | 2.06M | 1.96M | 841.00K | 113.00K | 13.00K |
| Stock-Based Compensation | 40.22M | 33.02M | 20.00M | 17.20M | 6.91M | 72.00K |
| Change in Working Capital | 6.44M | 1.02M | -6.11M | 2.26M | 9.22M | 389.00K |
| Operating Cash Flow | -82.23M | -43.81M | -50.58M | -42.92M | -16.98M | -4.37M |
| Capital Expenditures | -1.04M | -359.00K | -1.85M | -6.45M | -1.48M | 0 |
| Investing Cash Flow | -300.98M | -258.02M | -41.19M | 58.27M | -340.96M | 0 |
| Financing Cash Flow | 4.95M | 713.24M | 59.55M | 500.00K | 386.52M | 11.52M |
| Net Change in Cash | -378.27M | 411.40M | -32.22M | 15.84M | 28.59M | 7.16M |
| Free Cash Flow | -83.28M | -44.17M | -52.42M | -49.37M | -18.46M | -4.37M |
This table shows 6 annual periods of Janux Therapeutics's cash flow statement, from FY 2025 back to FY 2020, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow JANX's reporting calendar. What is a cash flow statement?